The Predictive Ability of 4MGS in IPF
IPFMORT
Does 4 Metre Gait Speed (4MGS) Predict Mortality and Non-elective Hospitalisation in Patients With Idiopathic Pulmonary Fibrosis (IPF)?
1 other identifier
observational
132
1 country
1
Brief Summary
This study investigates whether usual walking speed, measured by the 4 metre gait speed test (4MGS), and change in usual walking speed over 6 months predicts death and hospital admissions in patients with Idiopathic Pulmonary Fibrosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2015
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2015
CompletedFirst Submitted
Initial submission to the registry
May 1, 2015
CompletedFirst Posted
Study publicly available on registry
May 6, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 20, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
October 20, 2017
CompletedNovember 9, 2017
November 1, 2017
2.6 years
May 1, 2015
November 8, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mortality
IPF-specific and all-cause mortality
12 months
Secondary Outcomes (1)
Non-elective hospital admissions
12 months
Study Arms (1)
IPF_MORT
Patients diagnosed with Idiopathic Pulmonary Fibrosis according to NICE guidelines.
Interventions
Eligibility Criteria
Patients diagnosed with IPF according to NICE guidelines
You may qualify if:
- IPF diagnosis according to NICE guidelines
You may not qualify if:
- Significant co-morbidities that would limit walking ability, exercise capacity or make exercise unsafe (e.g. unstable ischaemic heart disease, neuromuscular disease, severe hip/lower limb joint pain, peripheral vascular disease, lower limb amputation)
- Any patient whom the chief investigator feels it is unsafe to exercise (e.g. unstable cardiovascular disease)
- Any condition that precludes providing informed consent e.g. cognitive impairment or poor English
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Royal Brompton and Harefield NHS Foundation Trust
Harefield, Middlesex, UB9 6JH, United Kingdom
Related Publications (1)
Nolan CM, Delogu V, Maddocks M, Patel S, Barker RE, Jones SE, Kon SSC, Maher TM, Cullinan P, Man WD. Validity, responsiveness and minimum clinically important difference of the incremental shuttle walk in idiopathic pulmonary fibrosis: a prospective study. Thorax. 2017 Sep 7:thoraxjnl-2017-210589. doi: 10.1136/thoraxjnl-2017-210589. Online ahead of print.
PMID: 28883090DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
William DC Man, MC, PhD
Royal Brompton and Harefield NHS Foundation Trust
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 1, 2015
First Posted
May 6, 2015
Study Start
March 1, 2015
Primary Completion
October 20, 2017
Study Completion
October 20, 2017
Last Updated
November 9, 2017
Record last verified: 2017-11